FDA
-
-
-
-
-
-
-
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
-
-
-
-
-
-
-
Akebia Therapeutics names Philip Vickers to board of directors
-
-
-
-
-
-
-
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
-
-
-
-
-
-
-
Akebia expands Vafseo access through IRC's 230 dialysis centers
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) Announces Positive Opinion of European Medicines Agency for XOANACYL
-
-
-
-
-
-
-
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
-
328,149 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

